Transaction DateRecipientSharesTypePriceValue
3rd September 2020Matthew Strobeck350Open or private purchase$155.64$54,474.00
3rd September 2020Matthew Strobeck50Open or private purchase$155.60$7,779.85
2nd September 2020Matthew Strobeck300Open or private purchase$167.74$50,320.50
2nd September 2020Matthew Strobeck7,000Open or private purchase$166.60$1,166,190.20
26th August 2020Jack W Schuler365,241Open or private purchase$4.25$1,552,274.25
1st July 2020Jack W Schuler2,285,715Open or private purchase$3.50$8,000,002.50
26th June 2020Jack W Schuler2,424,242Open or private purchase$1.65$3,999,999.30
26th June 2020Jack W Schuler5,151,517Open or private purchase$1.65$8,500,003.05
18th June 2020Romney Humphries3,000Exercise of derivative$5.93$17,790.00
18th June 2020Romney Humphries3,000Open or private sale$12.00$36,000.00
Accelerate Diagnostics
Accelerate Diagnostics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Accelerate Diagnostics, Inc. is an in vitro diagnostics company. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ. It focuses on developing and commercializing innovative instrumentation.


Ticker: AXDX
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 727207
Employees: 275
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $47 M (-22%)
Receivables, Net, Current: $3 M (-19%)
Inventory, Net: $9 M (0%)
Other Assets, Current: $1 M (-5%)
Assets, Current: $103 M (-15%)
Property, Plant and Equipment, Net: $8 M (0%)
Other Assets, Noncurrent: $734 Th (-2%)
Assets: $115 M (-14%)
Accounts Payable, Current: $3 M (14%)
Accrued Liabilities, Current: $3 M (-12%)
Liabilities, Current: $10 M (23%)
Other Liabilities, Noncurrent: $190 Th (900%)
Liabilities: $152 M (7%)
Common Stock, Shares, Issued: $56 M (2%)
Additional Paid in Capital, Common Stock: $463 M (2%)
Retained Earnings (Accumulated Deficit): $455 M (9%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $140 Th (141%)
Treasury Stock, Value: $451 Th (0%)
Stockholders' Equity (Parent): $37 M (0%)
Liabilities and Equity: $115 M (-14%)
Revenue: $2 M (0%)
Cost of Revenue: $1 M (-52%)
Gross Margin: $954 Th (-52%)
Research and Development: $5 M (-52%)
Operating Income/Loss: $16 M (-52%)
Other Income, net: $4 M (-50%)